J. Molina, P. Yang, S. Cassivi, S. Schild, A. Adjei et al., Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Available from: http://www.sciencedirect.com/science/article/pii Available from: http://invs.santepubliquefrance.fr/content/download Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non?Small- Cell Lung Cancer: A Randomized, Multicenter Phase III Trial, Mayo Clinic Proceedings [Internet]. Survie des personnes. J Clin Oncol, vol.43013222, issue.113, pp.584-5942602, 2004.

A. Wozniak, J. Crowley, S. Balcerzak, G. Weiss, C. Spiridonidis et al., Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study., Journal of Clinical Oncology, vol.16, issue.7, pp.2459-2465, 1998.
DOI : 10.1200/JCO.1998.16.7.2459

F. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla et al., Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non???Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy, Journal of Clinical Oncology, vol.18, issue.10, pp.2095-2103, 2000.
DOI : 10.1200/JCO.2000.18.10.2095

T. Lynch, D. Bell, R. Sordella, S. Gurubhagavatula, R. Okimoto et al., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2139, 2004.
DOI : 10.1056/NEJMoa040938

T. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-957, 2009.
DOI : 10.1056/NEJMoa0810699

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, The Lancet Oncology, vol.13, issue.3, pp.239-246, 2012.
DOI : 10.1016/S1470-2045(11)70393-X

J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2009.
DOI : 10.1056/NEJMoa1504627

H. Borghaei, L. Paz-ares, L. Horn, D. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015.
DOI : 10.1056/NEJMoa1507643

D. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-64, 2012.
DOI : 10.1038/nrc3237

A. Ribas, Tumor Immunotherapy Directed at PD-1, New England Journal of Medicine, vol.366, issue.26, pp.2517-2519, 2012.
DOI : 10.1056/NEJMe1205943

C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio et al., Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015.
DOI : 10.1056/NEJMoa1412082

URL : https://hal.archives-ouvertes.fr/hal-00699117

R. Motzer, B. Escudier, D. Mcdermott, S. George, H. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015.
DOI : 10.1056/NEJMoa1510665

M. Reck, Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016.
DOI : 10.1056/NEJMoa1606774

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, The Lancet, vol.389, issue.10066, pp.255-65, 2017.
DOI : 10.1016/S0140-6736(16)32517-X

S. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Durvalumab after Chemoradiotherapy in Stage III Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.20, 2017.
DOI : 10.1056/NEJMoa1709937

J. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel et al., Immune-related adverse events with immune checkpoint blockade: a comprehensive review, European Journal of Cancer, vol.54, 2016.
DOI : 10.1016/j.ejca.2015.11.016

H. Montaudié, J. Pradelli, T. Passeron, J. Lacour, and S. Leroy, Pulmonary sarcoid-like granulomatosis induced by nivolumab, British Journal of Dermatology, vol.22, issue.4, pp.1060-1063
DOI : 10.1158/1078-0432.CCR-15-1136

H. Teulings, J. Limpens, S. Jansen, A. Zwinderman, J. Reitsma et al., Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis, Journal of Clinical Oncology, vol.33, issue.7, 2015.
DOI : 10.1200/JCO.2014.57.4756

N. Shaverdian, A. Lisberg, K. Bornazyan, D. Veruttipong, J. Goldman et al., Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-smallcell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol, 2017.

A. Padhani and L. Ollivier, The RECIST criteria: implications for diagnostic radiologists, The British Journal of Radiology, vol.74, issue.887, pp.983-986, 2001.
DOI : 10.1002/1097-0142(19800901)46:5<1286::AID-CNCR2820460533>3.0.CO;2-F

R. Wahl, H. Jacene, Y. Kasamon, and M. Lodge, From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, Journal of Nuclear Medicine, vol.50, issue.Suppl_1, pp.122-150, 2009.
DOI : 10.2967/jnumed.108.057307

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

M. Nishino, A. Giobbie-hurder, M. Gargano, M. Suda, N. Ramaiya et al., Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements, Clinical Cancer Research, vol.19, issue.14, pp.3936-3979, 2013.
DOI : 10.1158/1078-0432.CCR-13-0895

S. Cho, E. Lipson, H. Im, S. Rowe, E. Gonzalez et al., F-FDG PET/CT Imaging in Patients with Advanced Melanoma, Journal of Nuclear Medicine, vol.58, issue.9, pp.1421-1429, 2017.
DOI : 10.2967/jnumed.116.188839

D. Spigel, L. Schwartzberg, D. Waterhouse, J. Chandler, M. Hussein et al., 02c-026 Is nivolumab safe and effective in ederly and PS2 patients with non small cell lung cancer (NSCLC)? Results of Checkmate 153, J Thorac Oncol, vol.12, issue.1, pp.1286-1287, 2017.

J. Judd, M. Zibelman, E. Handorf, O. Neill, J. Ramamurthy et al., Immune???Related Adverse Events as a Biomarker in Non???Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors, The Oncologist, vol.22, issue.10
DOI : 10.1634/theoncologist.2017-0133

. Inhibitors, The Oncologist, pp.2017-0133, 2017.

J. Osorio, A. Ni, J. Chaft, R. Pollina, M. Kasler et al., Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer, Annals of Oncology, vol.640, 2016.
DOI : 10.1093/annonc/mdw640

R. Schouten, P. Baas, M. Van-den-heuvel, V. Leeuwenhoek, and A. Ma14, Real life experience with immunotherapy in Netherlands, J Thorac Oncol, vol.0712, issue.1, p.425, 2017.

T. Funazo, T. Nomizo, and Y. Kim, Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non???Small Cell Lung Cancer Treated with Nivolumab, Journal of Thoracic Oncology, vol.12, issue.9, 2017.
DOI : 10.1016/j.jtho.2017.04.027

Y. Kataoka, N. Ebi, D. Fujimoto, S. Hara, K. Hirano et al., Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study, Annals of Oncology, vol.51, issue.5, pp.1402-1402, 2017.
DOI : 10.1016/S0959-8049(16)31443-5

S. Bagley, S. Kothari, C. Aggarwal, J. Bauml, E. Alley et al., Pretreatment neutrophil-tolymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-smallcell lung cancer, Lung Cancer, vol.2017106, pp.1-7